70+
Study Sites
Headquartered at Fred Hutch in Seattle, the Network includes over 70 sites on four continents staffed by teams with expertise in vaccinology, immunology, and in conducting clinical trials.
100+
Clinical Trials
For more than 20 years, the HVTN has conducted all phases of clinical trials based on the latest developments in vaccinology and immunology for the prevention of HIV, tuberculosis and COVID-19.
74
Scholar Awards
We are investing in the next generation of HIV prevention researchers with grants and mentoring for African American/Black and Hispanic/Latinx medical students.
HVTN Mission
Our mission is to fully characterize the safety, immunogenicity, and efficacy of HIV vaccine candidates with the goal of developing a safe, effective vaccine as rapidly as possible for prevention of HIV globally.
Who We Are
We are the world’s largest publicly-funded international collaboration focused on the evaluation of vaccines to prevent HIV/AIDS.
What We Do
Our sites conduct all phases of clinical trials — from evaluating experimental vaccines for safety and immunogenicity to testing vaccine efficacy.
Get Involved
Worldwide, thousands of people have participated in HIV vaccine trials. Volunteers are the heroes of vaccine development.
It Takes a Village
The HIV Vaccine Trials Network is an international partnership of research scientists, clinical trial sites, laboratories, statisticians, regulators and ethicists, participants, volunteers and community representatives working with industry, academia, and governments in the global search for a preventive HIV vaccine.
Recent HVTN News & Announcements
February 7 is National Black HIV/AIDS Awareness Day
On this National Black HIV/AIDS Awareness Day, with the theme of: “Together...We Can Make HIV Black History!”, HVTN/CoVPN's Louis Shackelford writes about faith and envisioning a world without HIV.
Request for Research Proposals: Imbokodo HIV Vaccine Efficacy Trial (HVT 705/VAC89220HPX2008)
The HIV Vaccine Trials Network (HVTN), the NIH/NIAID Division of AIDS (DAIDS), and Janssen Vaccines and Prevention are pleased to welcome scientific study proposals involving specimens and/or study data from the Imbokodo (HVTN 705/VAC89220HPX2008) HIV vaccine clinical trial.
Read the Latest Community Compass Issue
In this issue, we acknowledge the recent passing of our dear colleague and long-time HIV activist Giulio Corbelli, a recent announcement of Dr. Anthony Fauci stepping down from his role as Director of NIAID, a recent statement from experts regarding the importance of including people living with HIV in TB research, along with many other HVTN updates.
